A novel test that can help predict whether any microbicide against HIV is safe for human use has been developed by researchers at the Albert Einstein College of Medicine of Yeshiva University.
For years, scientists have been trying to develop a topical vaginal microbicide for preventing transmission of HIV, the virus that causes AIDS.
AIDS/HIV - Prevention And Transmission
Encyclopedia section of medindia explains in brief about the prevention for AIDS/HIV
Advertisement
Several microbicide gels have been assessed in clinical trials after passing laboratory and animal safety tests.
However, all the microbicides were found to be ineffective against HIV, and two of the gels - nonoxynol-9 and cellulose sulfate - actually increased the risk of HIV infection in women.
![AIDS / HIV - Treatment]( "AIDS / HIV - Treatment")
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV
"Our goal was to develop assays that are predictive of safety before proceeding to clinical trials that typically cost millions of dollars, involve thousands of women, and take many years," said study leader Dr Betsy C. Herold, a professor at Einstein.
While evaluating a microbicide's safety, the researchers look primarily for signs that the chemical inflames cells of the vaginal lining, or epithelium.
Tight junctions between genital tract epithelial cells provide an anatomic barrier, and prevent HIV from reaching submucosal targets.
Microbicides that disrupt the barrier increase the risk for HIV infection.
According to the Dr. Herold, this assay may help in predicting the safety of microbicides.
"Our findings strongly suggest that microbicides can increase the risk of HIV infection through a mechanism other that inflammation - namely, by disrupting the protective epithelial cell barrier," said Herold.
"If confirmed by further study, this assay should be used early on to screen for microbicide safety before advancing a product to clinical trials involving thousands of women," she added.
The study has been published in the Journal of Infectious Diseases.
Source: ANI
RAS
AIDS / HIV - Treatment
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV
Advertisement
"Our goal was to develop assays that are predictive of safety before proceeding to clinical trials that typically cost millions of dollars, involve thousands of women, and take many years," said study leader Dr Betsy C. Herold, a professor at Einstein.
While evaluating a microbicide's safety, the researchers look primarily for signs that the chemical inflames cells of the vaginal lining, or epithelium.
Tight junctions between genital tract epithelial cells provide an anatomic barrier, and prevent HIV from reaching submucosal targets.
Microbicides that disrupt the barrier increase the risk for HIV infection.
According to the Dr. Herold, this assay may help in predicting the safety of microbicides.
"Our findings strongly suggest that microbicides can increase the risk of HIV infection through a mechanism other that inflammation - namely, by disrupting the protective epithelial cell barrier," said Herold.
"If confirmed by further study, this assay should be used early on to screen for microbicide safety before advancing a product to clinical trials involving thousands of women," she added.
The study has been published in the Journal of Infectious Diseases.
Source: ANI
RAS
Advertisement
 AIDS/HIV - Clinical FeaturesEncyclopedia section of medindia gives general info about HIV Clinical Features | Advertisement
|
Advertisement
Recommended Readings
Latest AIDS/HIV News
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.
In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.
Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.
Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.
DNA editing tool CRISPR-Cas13 helps diagnose and signal the presence of HIV antibodies in HIV patients.
